Doyle Patricia, Düren Christian, Nerlich Kai, Verburg Frederik A, Grelle Inge, Jahn Hanne, Fassnacht Martin, Mäder Uwe, Reiners Christoph, Luster Markus
Department of Nuclear Medicine, University of Würzburg, Josef-Schneider-Strasse 2, Würzburg, Germany.
J Clin Endocrinol Metab. 2009 Aug;94(8):2970-4. doi: 10.1210/jc.2008-2403. Epub 2009 Jun 2.
The objectives of the study was to compare pentagastrin- and calcium-stimulated serum human calcitonin (hCT) levels for nonsmoking healthy adults without evidence of thyroid disorders and determine reference ranges of basal and pentagastrin- and calcium-stimulated serum hCT levels.
This was a healthy volunteer study including within-group and intergroup comparisons.
The study was conducted at a tertiary referral center.
Subjects included 50 healthy, nonsmoking volunteers (25 female; aged 22-57 yr) without evidence of thyroid abnormality.
hCT was measured using a calcitonin two-site automated chemiluminescent immunometric assay (the most common hCT assay in clinical practice) in serum samples obtained before and 2, 5, and 15 min after iv stimulation using pentagastrin, 0.5 microg/kg body weight, or calcium gluconate, 2.5 mg/kg.
Reference ranges for basal, unstimulated, and pentagastrin- or calcium-stimulated hCT and pentagastrin and calcium tolerability in healthy adults were measured.
The 95th percentile basal hCT values did not differ between males and females (5.0 vs. 5.7 pg/ml). The 95th percentile maximal stimulated hCT values rose distinctly after pentagastrin (peak men, 37.8 pg/ml; women, 26.2 pg/ml) and even more so after calcium (peak men, 131.1 pg/ml, women, 90.2 pg/ml). No hCT increase was detected in four of 25 men and 12 of 25 women after pentagastrin vs. none of 24 men and two of 18 women after calcium. Calcium was associated with fewer and less intense adverse effects than was pentagastrin.
High-dose calcium is a more potent and better-tolerated hCT stimulator than is pentagastrin. The reference ranges for basal and stimulated hCT established via automated chemiluminescent assay were lower than those reported for other assays.
本研究的目的是比较五肽胃泌素和钙刺激下无甲状腺疾病证据的非吸烟健康成年人血清人降钙素(hCT)水平,并确定基础、五肽胃泌素和钙刺激下血清hCT水平的参考范围。
这是一项包括组内和组间比较的健康志愿者研究。
研究在一家三级转诊中心进行。
受试者包括50名无甲状腺异常证据的健康非吸烟志愿者(25名女性;年龄22 - 57岁)。
使用降钙素双位点自动化学发光免疫测定法(临床实践中最常用的hCT测定法),在静脉注射0.5μg/kg体重的五肽胃泌素或2.5mg/kg葡萄糖酸钙刺激前及刺激后2、5和15分钟采集的血清样本中测量hCT。
测量健康成年人基础、未刺激及五肽胃泌素或钙刺激下hCT的参考范围以及五肽胃泌素和钙的耐受性。
男性和女性第95百分位数的基础hCT值无差异(分别为5.0和5.7pg/ml)。五肽胃泌素刺激后第95百分位数的最大刺激hCT值明显升高(男性峰值为37.8pg/ml;女性为26.2pg/ml),钙刺激后升高更明显(男性峰值为131.1pg/ml,女性为90.2pg/ml)。五肽胃泌素刺激后,25名男性中有4名、25名女性中有12名未检测到hCT升高;钙刺激后,24名男性中无一例、18名女性中有2名未检测到hCT升高。与五肽胃泌素相比,钙引起的不良反应更少且程度更轻。
高剂量钙是比五肽胃泌素更有效的hCT刺激剂,且耐受性更好。通过自动化学发光测定法确定的基础和刺激后hCT参考范围低于其他测定法报告的范围。